Latest News and Press Releases

Dosing of the first patient in the Phase 1 clinical trial of ADCX-020.

Präsentationen zeigen Fortschritte in BioNTechs spätklinischen Programmen im Bereich Lungenkrebs und unterstreichen das Potenzial des differenzierten Unternehmensportfolios, welches Immunmodulatoren,...

Presentations showcase progress in BioNTech’s late-stage lung cancer programs, reinforcing the potential of the Company’s differentiated portfolio spanning immunomodulators, antibody-drug conjugates,...

Data presented at 16th World ADC London Summit with lead programme in colorectal cancer highlight the promise of Promatix’s proteomics-based platform to optimise cis-bispecific antibody-drug conjugate...

The collaboration will inform patient selection for treatment with STX-1, a first-in-class senolytic ADC directed against DPP4/CD26.

Adcytherix Powers Ahead: Technology and Team in Place to Deliver Strategy and Build an ADC Powerhouse Adcytherix reinforces its Executive Committee with two pivotal appointments: CMO and CFOThe ADCX...

IntoCell and Xcellon Biologics partner to expand ADC development access, combining IntoCell's OHPAS payload-linker platform with Xcellon's CDMO expertise.

ICP-B794 has demonstrated superior anti-tumor activity in animal models, and exhibited significant tumor-killing effects even in large tumors.

Leveraging deep scientific and clinical expertise in MPNs to drive a pipeline of disease-modifying precision therapies that selectively target disease-driving cellsAdvancing AT-01, a first-in-class...

Adcytherix lève 105 millions d’euros pour accélérer le développement de son portefeuille d‘anticorps conjugués de nouvelle génération intégrant de nouveaux agents cytotoxiques. Le tour de table est...